Sequoia Financial Advisors LLC Has $1.73 Million Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Sequoia Financial Advisors LLC lowered its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 92.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,357 shares of the medical equipment provider's stock after selling 199,840 shares during the quarter. Sequoia Financial Advisors LLC's holdings in Zimmer Biomet were worth $1,728,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Stonebridge Financial Group LLC purchased a new stake in Zimmer Biomet in the 4th quarter worth approximately $25,000. Dunhill Financial LLC raised its holdings in shares of Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 218 shares in the last quarter. Ashton Thomas Securities LLC acquired a new stake in Zimmer Biomet during the third quarter valued at $28,000. Brooklyn Investment Group acquired a new stake in Zimmer Biomet during the third quarter valued at $35,000. Finally, Kentucky Trust Co acquired a new stake in Zimmer Biomet during the fourth quarter valued at $39,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.95% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ZBH. JMP Securities reissued a "market outperform" rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. Raymond James reduced their price objective on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. JPMorgan Chase & Co. raised Zimmer Biomet from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Royal Bank of Canada reduced their price objective on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Finally, Stifel Nicolaus lifted their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research report on Thursday, January 23rd. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $124.15.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH traded up $0.03 during trading hours on Wednesday, hitting $112.91. 1,916,613 shares of the company's stock were exchanged, compared to its average volume of 1,487,508. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The stock has a market capitalization of $22.48 billion, a price-to-earnings ratio of 25.37, a PEG ratio of 1.95 and a beta of 1.04. The company's 50-day moving average price is $106.18 and its 200-day moving average price is $106.88.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the firm posted $2.20 earnings per share. On average, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.85%. Zimmer Biomet's dividend payout ratio is 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.